Previous 10 | Next 10 |
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “As we move toward reporting more mature interim overall survival (OS) results from our TIVO-3 study of tivozanib in advanced kidney cancer, AVEO...
AVEO Oncology (NASDAQ: AVEO ) and Kyowa Kirin Co., Ltd. ( OTCPK:KYKOF ) have amended their license agreement allowing the latter to repurchase the non-oncology rights to tivozanib in AVEO territories, including the U.S. and EU. Under their original 2006 contract, AVEO had exclusive rights ...
Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) and AVEO Oncology (NASDAQ: AVEO) announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which includes the U.S. and EU. The agreement is an amendment to ...
AVEO Pharmaceuticals (AVEO) has had a rough go so far in 2019, and the stock has reflected that by plummeting over 50% since the beginning of the year. AVEO had a major holdup when it had to defer FOTIVDA's NDA submission for the 3rd-line treatment of advanced renal cell carcinoma "RCC" in J...
AVEO Oncology ( AVEO ) investors have been promised with new trial readout in August this year. However, while the company has failed multiple times to get approval for tivozanib, other competitors have emerged and brought in new therapy methods for renal cell carcinoma ((RCC)). Besides that, ...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was in the red last week, dropping from 3,279.52 points on Tuesday (May 28) to 3,167.47 points as of 1:36 p.m. EDT on Friday (May 31). Despite the index’s dip, a number of NASDAQ biotech and pharma stocks still had notable share price...
AVEO Oncology (NASDAQ: AVEO) today announced that Mike Ferraresso, Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.m. EDT. A live webcast of the presentation ca...
AVEO Oncology (NASDAQ: AVEO) today announced two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois. Presentation Details Title: Efficacy and safety of tivozanib in recurrent, platin...
AVEO Pharmaceuticals (NASDAQ: AVEO ): Q1 GAAP EPS of -$0.06 in-line. More news on: AVEO Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update. “With a successful recent equity offering, together with the triggering of a FOTIVDA ® (tivozanib) milestone from EUSA, AVEO’s stre...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...